Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Revenue of Lipocine Inc. (LPCN)
Revenue in 2023 (TTM): $-2,850,818
According to Lipocine Inc.'s latest financial reports the company's current revenue (TTM) is $-2,850,818. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Lipocine Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $-2,850,818 | $-2,850,818 | $-16,322,666 | $-16,351,327 | $-16,352,082 |
| 2022 | $500 K | $500 K | $-10,721,404 | $-10,757,955 | $-10,758,636 |
| 2021 | $16.14 M | $16.14 M | $-430,527 | $-634,199 | $-634,399 |
| 2020 | $ | $ | $-17,992,710 | $-20,964,619 | $-20,964,819 |
| 2019 | $164.99 K | $164.99 K | $-12,648,447 | $-13,007,144 | $-13,007,344 |
| 2018 | $428.03 K | $428.03 K | $-11,307,224 | $-11,659,322 | $-11,660,022 |
| 2017 | $ | $ | $-21,189,606 | $-20,982,160 | $-20,982,860 |
| 2016 | $ | $ | $-18,938,794 | $-18,970,756 | $-18,971,508 |
| 2015 | $ | $ | $-18,355,347 | $-18,208,178 | $-18,208,378 |
| 2014 | $ | $ | $-20,466,194 | $-20,372,476 | $-20,372,676 |
| 2013 | $ | $ | $-10,623,387 | $-10,645,154 | $-10,590,106 |
| 2012 | $7.71 M | $5.43 M | $-76,654 | $3.89 M | $3.8 M |
| 2011 | $ | $ | $-5,162 | $-5,162 | $-5,162 |